Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers

Inclusion Criteria:

1. Progressive HER2 positive solid tumours (immunohistochemistry [IHC] positive or
equivocal) with no available standard or curative treatment.

2. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.

Exclusion Criteria:

1. Active infectious disease considered by the Investigator to be incompatible with the
protocol.

2. Patients not recovered from any therapy-related toxicities from previous therapies to
at least CTCAE ≤ Grade 1 except in case of liver metastases or Gilbert's Syndrome or
alopecia.

3. Brain metastases that are symptomatic or untreated or that require current therapy.

4. Previous treatment with immunotherapy within 8 weeks of starting study medication,
chemotherapy, radiotherapy, molecular-targeted therapy, or biological therapies
(including HER2 directed therapies) within 4 weeks of starting study medication, or
hormone therapy within 2 weeks of starting study medication.

5. Use of any investigational drug within the past 4 weeks before start of study
medication or concomitantly with this study except for investigational
immune-stimulatory therapy (e.g. checkpoint-regulator targeted treatment). The minimum
washout period should be 8 weeks before starting the study medication.